Sigachi Industries Ltd, established in 1989, is India's first and leading manufacturer of high-quality microcrystalline cellulose (MCC) for the pharmaceutical and food industry. The company is India's largest producer of Microcrystalline Cellulose (MCC) and continues to set new benchmarks in global pharmaceutical excipients while strategically expanding into Active Pharmaceutical Ingredients (APIs) and specialty chemicals.
Since its inception, Sigachi's aspiration to create substantial value for all its stakeholders drove the evolution from being a market leader of MCC Excipients to a dynamic, diversified enterprise with a robust presence in Active Pharmaceutical Ingredients (APIs), Food and Nutrition, Operations & Management, and the Personal Care industry. With robust financial growth, a diversified portfolio, and an expanding global footprint, Sigachi is now powering ahead as a vertically integrated pharmaceutical player.
Sigachi's state-of-the-art manufacturing facilities, strategically located in Hyderabad, Sultanpur, Jhagadia, Dahej, and Raichur, are equipped to deliver highly tailored solutions that cater to the specific needs of their diverse customer base. These facilities ensure seamless supply chain reliability, serving clients across the globe. Sigachi's dominance in MCC is rooted in its five world-class manufacturing units in Hyderabad, Dahej, Jhagadia, Raichur, and Sultanpur, with three facilities dedicated solely to MCC.
The company's manufacturing capacity of 22,000 MTPA (operating at over 80% utilisation) makes it not just India's largest, but also among the Top 5 MCC manufacturers globally. All facilities are certified with USFDA, EDQM, EXCiPACT, ISO 9001, ISO 14001, and ISO 45001, enabling global customers to meet the highest quality and compliance standards.
Since its inception in 1989, Sigachi Group has become a leading global manufacturer of microcrystalline cellulose and a key player in Excipients and Active Pharmaceutical Ingredients (APIs), exporting 70% of its production to over 60 countries. Aligned with its ethos of customer centricity, Sigachi established subsidiaries in UAE and USA to be closer to its clients and improve responsiveness.
Sigachi operates in three different segments which include pharma, food & nutra and cosmetics. Out of these segments, Sigachi industries generated 75% of its revenue from pharma followed by food & nutra 20% and cosmetics occupies for 5%. The company's diverse product portfolio encompasses Active Pharmaceutical Ingredients (APIs), Intermediates, Excipients, vitamin-mineral blends, and Operations and Management (O&M) services.
The company's MCC products serve as critical components in pharmaceutical manufacturing. Sigachi industries play a major role through their production of Microcrystalline Cellulose (MCC). MCC being a non medicinal ingredient plays a critical role in formulating tablets, capsules and other dosage forms. Sigachi's MCC acts as a binder, bulking agent and a disintegrant. The company's proprietary DAPOBAL® process, in-house acid recovery, and 60+ MCC grades support customers ranging from global generics to premium innovators.
As of recent data, Sigachi Industries has a market capitalization of ₹1,601 crore. In FY25, the company posted a 46.21% EBITDA growth and a 25.42% revenue surge to ₹5,003 million, driven by excipient demand, API capacity expansions, and strategic partnerships across 65+ countries. The company has delivered an EBITDA margin of 22.38% and 14.09% PAT for the same period.
The year continues Sigachi's impressive performance over the last five years, where it has tripled core revenues, achieved 28% PAT CAGR, and maintained low debt and strong operating margins.
- Market Capitalization: ₹1,601 crore (as of recent data)
- FY25 Revenue: ₹5,003 million (25.42% growth)
- FY25 EBITDA Growth: 46.21%
- FY25 EBITDA Margin: 22.38%
- FY25 PAT Margin: 14.09%
- Sales FY2025: ₹488.24 crore (22.38% increase YoY)
- Net Profit FY2025: ₹69.56 crore (21.65% increase YoY)
- Promoter Holding: 44.14% (as of Mar 2025, down from 44.71% in Dec 2024)
Sigachi has received Terms of Reference (ToR) approval from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh, for a cutting-edge Bulk Drugs and Specialty Chemicals facility in Orvakal, Kurnool District. Spread over 25.09 acres in Guttapadu-Orvakal node, development starts August 1, 2025, post EC process initiation from July 15, 2025.
Sigachi has acquired an 80% stake in Trimax BioSciences, a leading API (active pharmaceutical ingredient) manufacturing company based in Raichur. This acquisition gives Sigachi the complete ecosystem of the pharmaceutical industry, expanding its capabilities beyond excipients. Trimax Biosciences, a Sigachi Group Company has successfully achieved the Certificate of Suitability (CEP) for 'Metformin Hydrochloride' from European Directorate for the Quality of Medicines & Health Care (EDQM). This milestone paves the way for Trimax to export this crucial Active Pharmaceutical Ingredient (API) to Europe and other CEP-accepting markets.
Sigachi's Government of India-approved R&D Laboratory, combined with a cutting-edge Excipient Application Lab, exemplifies the company's commitment to continuous innovation and technical excellence. Two DSIR-certified R&D centres in Hyderabad and Dahej fuel Sigachi's innovation, backed by 7 patents, 46 trademarks, and advanced QbD development frameworks. A new API & Analytical R&D Centre in Hyderabad, launching in Q1 FY26, will centralise formulation research, data science, and excipient compatibility modelling.
With 98% ESG-compliant vendors, 100% sustainable packaging, and social impact programmes reaching over 12,600 lives, Sigachi is also a sustainability champion in pharma manufacturing. The company's commitment to environmental responsibility is evident in its sustainable manufacturing practices and regulatory compliance across all facilities.
- Leadership Appointment: In July 2025, the company appointed Lijo Stephen Chacko as Deputy Group CEO effective July 7, 2025.
- Operational Challenge: The company faced operational challenges with a fire accident at the Sigachi plant that caused casualties and resulted in operations being suspended for 90 days.
- Credit Rating Reaffirmation: CARE reaffirmed Sigachi's credit rating despite the fire at the Hyderabad unit impacting 20% revenue, with the rating on watch negative.
The company continues to focus on strategic growth initiatives and maintaining its leadership position in the global pharmaceutical excipients market while expanding its API manufacturing capabilities to become a fully integrated pharmaceutical company.
